Literature DB >> 19187290

Posttraumatic epilepsy: the endophenotypes of a human model of epileptogenesis.

Ramon Diaz-Arrastia1, Mark A Agostini, Christopher J Madden, Paul C Van Ness.   

Abstract

Posttraumatic epilepsy is a common complication of traumatic brain injury (TBI), occurring in up to 15-20% of patients with severe brain trauma. Trauma accounts for approximately 5% of chronic epilepsy in the community. Because it is a common condition, and because of the relatively short latency period between injury and onset of chronic seizures, posttraumatic epilepsy represents a good model to test antiepileptogenic therapies. However, several well-conducted clinical trials have failed to demonstrate antiepileptogenic efficacy for several common anticonvulsants. Posttraumatic epilepsy can arise through a number of mechanisms, which often coexist within a single patient. Penetrating brain injury produces a cicatrix in the cortex and is associated with a risk of posttraumatic epilepsy of approximately 50%, whereas nonpenetrating head injury may produce focal contusions and intracranial hemorrhages, and is associated with a risk of posttraumatic epilepsy of up to 30%. Furthermore, closed head injury often produces diffuse concussive injury, with shearing of axons and selective damage to vulnerable brain regions, such as the hippocampus. The clinical, neurophysiologic, imaging, and neuropathologic features or epileptogenicity differ between these alternate mechanisms. It is likely that better understanding of the subtypes of epilepsy resulting from brain trauma will be required to successfully identify antiepileptogenic therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187290     DOI: 10.1111/j.1528-1167.2008.02006.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  32 in total

1.  Point.

Authors:  Raimondo D'Ambrosio; John W Miller
Journal:  Epilepsy Curr       Date:  2010-07       Impact factor: 7.500

2.  Correlates of posttraumatic epilepsy 35 years following combat brain injury.

Authors:  V Raymont; A M Salazar; R Lipsky; D Goldman; G Tasick; J Grafman
Journal:  Neurology       Date:  2010-07-20       Impact factor: 9.910

3.  Early seizures and temporal lobe trauma predict post-traumatic epilepsy: A longitudinal study.

Authors:  Meral A Tubi; Evan Lutkenhoff; Manuel Buitrago Blanco; David McArthur; Pablo Villablanca; Benjamin Ellingson; Ramon Diaz-Arrastia; Paul Van Ness; Courtney Real; Vikesh Shrestha; Jerome Engel; Paul M Vespa
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

Review 4.  Is epilepsy a preventable disorder? New evidence from animal models.

Authors:  Kathryn A Giblin; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2010-06       Impact factor: 7.519

5.  Post-traumatic epilepsy: an overview.

Authors:  Rebecca M Verellen; Jose E Cavazos
Journal:  Therapy       Date:  2010-09

6.  Surgical Outcomes in Post-Traumatic Epilepsy: A Single Institutional Experience.

Authors:  Frederick L Hitti; Matthew Piazza; Saurabh Sinha; Svetlana Kvint; Eric Hudgins; Gordon Baltuch; Ramon Diaz-Arrastia; Kathryn A Davis; Brian Litt; Timothy Lucas; H Isaac Chen
Journal:  Oper Neurosurg (Hagerstown)       Date:  2020-01-01       Impact factor: 2.703

7.  The Patient Repository for EEG Data + Computational Tools (PRED+CT).

Authors:  James F Cavanagh; Arthur Napolitano; Christopher Wu; Abdullah Mueen
Journal:  Front Neuroinform       Date:  2017-11-21       Impact factor: 4.081

Review 8.  Protein biomarkers of epileptogenicity after traumatic brain injury.

Authors:  Denes V Agoston; Alaa Kamnaksh
Journal:  Neurobiol Dis       Date:  2018-07-17       Impact factor: 5.996

Review 9.  Forebrain neurogenesis after focal Ischemic and traumatic brain injury.

Authors:  Steven G Kernie; Jack M Parent
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

10.  Introduction. Posttraumatic epilepsy: treatable epileptogenesis.

Authors:  Frances E Jensen
Journal:  Epilepsia       Date:  2009-02       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.